Aurisco Pharmaceutical Co., Ltd. announced that its application to issue convertible corporate bonds to unspecified objects has been approved and registered by the China Securities Regulatory Commission.
Orient Pharmaceutical Co., Ltd. 2023 Annual Equity Distribution Implementation Notice
Announcement of Resolutions of the 2023 Annual General Meeting of Shareholders of Orient Pharmaceutical Co., Ltd.
Legal Opinion of Guohao Law Firm (Hangzhou) on the 2023 Annual General Meeting of Shareholders of Orient Pharmaceutical Co., Ltd.
An indicative announcement by Orient Pharmaceutical Co., Ltd. on the issuance of convertible corporate bonds to unspecified targets and updates to application documents such as prospectus and responses to review inquiries
Orient Pharmaceutical Co., Ltd. Prospectus for Issuing Convertible Corporate Bonds to Unspecified Targets (2023 Financial Data Update)
Response Report on the Implementation Letter of Opinions of the Listing Review Committee Meeting on the Issuance of Convertible Corporate Bonds by Orient Pharmaceutical Co., Ltd. to Unspecified Targets (2023 Financial Data Update)
Response Report to the Second Round Review Inquiry Letter on Orient Pharmaceutical Co., Ltd.'s Application Documents for Issuance of Convertible Corporate Bonds to Unspecified Targets (2023 Financial Data Update)
Response Report to the Audit Inquiry Letter on Orient Pharmaceutical Co., Ltd.'s Application Documents for Issuance of Convertible Corporate Bonds to Unspecified Targets (2023 Financial Data Update)
Tianjian Certified Public Accountants (Special General Partnership) Financial Report and Audit Report on the Issuance of Convertible Corporate Bonds by Orient Pharmaceutical Co., Ltd. to unspecified targets (2023 Annual Financial Data Update)
Guo Hao (Hangzhou) Law Firm's Supplementary Legal Opinion on the Issuance of Convertible Corporate Bonds to Unspecified Targets by Orient Pharmaceutical Co., Ltd. (5)
Haitong Securities Co., Ltd. listing sponsorship for Orient Pharmaceutical Co., Ltd. to issue convertible corporate bonds to unspecified targets (2023 financial data update)
Haitong Securities Co., Ltd.'s letter of sponsorship for the issuance of convertible corporate bonds by Orient Pharmaceutical Co., Ltd. to unspecified targets (2023 financial data update)
Instructions from Tianjian Certified Public Accountants (Special General Partnership) on financial matters in the review inquiry letter of Orient Pharmaceutical Co., Ltd.'s application documents for the issuance of convertible corporate bonds to unspecified targets (2023 financial data update version)
Orient Pharmaceutical Co., Ltd. 2023 Annual General Meeting of Shareholders Meeting Materials
Announcement of Orient Pharmaceutical Co., Ltd. on the progress of providing guarantees for wholly-owned subsidiaries
Announcement of Resolutions of the 6th Meeting of the Third Board of Supervisors of Orient Pharmaceutical Co., Ltd.
Announcement of Orient Pharmaceutical Co., Ltd. on the use of idle own funds for entrusted financial management
Announcement of Orient Pharmaceutical Co., Ltd. on changes in accounting policies
Report on the performance of supervisory duties by the Audit Committee of the Board of Directors of Orient Pharmaceutical Co., Ltd. on accounting firms in 2023
No Data